On November 13, 2026, Health Canada approved FOUNDAYO® (orforglipron capsules) for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) ≥ 30 kg/m² (obesity) or overweight (BMI ≥ 27 kg/m²) in the presence of at least one weight-related comorbidity, and to improve glycemic control in adults with type 2 diabetes.

FOUNDAYO (orforglipron) is indicated as an adjunct to a healthy diet and physical activity:

- For weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) of:
  - 30 kg/m² or greater (obesity), or
  - 27 kg/m² to less than 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
- For the treatment of adult patients with type 2 diabetes to improve glycemic control:
  - As monotherapy when metformin is considered inappropriate due to intolerance or contraindication.
  - In combination with other medicinal products for the treatment of diabetes.